Compelo Medical Devices is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More
Close
Dismiss

Swedish Cancer Institute, Elekta Renew Partnership Agreement

Swedish Cancer Institute (Seattle) and Elekta have recently finalized a strategic partnership to launch a major new cancer-care initiative to transform radiation oncology delivery for cancer patients.

The multi-year, multi-product collaboration covers the spectrum of cancer management from treatment planning and delivery to workflow and connectivity and enhances Swedish Cancer Institute’s ability to provide patients access to technology early in the product introduction cycle.

The partnership agreement, which is among the comprehensive in Elekta’s history, includes Swedish’s acquisition of multiple cancer management solutions, including radiation-therapy treatment systems, treatment planning workstations, electronic medical record systems, clinical service, and a Leksell Gamma Knife Perfexion (radiosurgery) system. Elekta will also provide expertise in process transformation, technology enablement and strategic marketing.

Officials from Swedish and Elekta believe the combination of both organizations’ collective expertise, talents and resources will help deliver transformational benefits to the Cancer Institute’s patient population.

Swedish Cancer Institute, through its Center for Advanced Targeted Radiotherapies (CATRT), works collaboratively with technology partners to optimize clinical tools and practices early in the innovation cycle.

As per the agreement, Elekta will also deploy its technology and strategy experts alongside Swedish Cancer Institute’s key physicians, clinicians and administrators to ensure that the priority is placed on implementing successive phases of the agreement.

In addition, the partnership includes establishment of Swedish Cancer Institute as a customer training facility, clinical product development center, and global reference site for Elekta.

Tomas Puusepp, president and CEO of Elekta, said: “The agreement is mutually beneficial for both organizations. Elekta will contribute its innovative technologies and significant experience in the oncology marketplace to further elevate Swedish’s position as a cancer-care leader. And in turn, Elekta will benefit from the unique opportunity to partner with one of the most forward-thinking cancer-care institutions in the US.”